Fortis Healthcare Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.
FORTIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fortis Healthcare's Board approved audited standalone and consolidated results for Q4 and FY25 on May 20, 2025. Standalone revenue from operations grew ~22.4% YoY to ₹1,445.9 crore (₹1,181.4 crore in FY24), while EBITDA expanded to ₹454.1 crore from ₹335.8 crore, reflecting margin expansion. However, reported net profit for FY25 fell sharply to ₹63.8 crore from ₹199.5 crore, weighed down by an exceptional loss of ₹115.1 crore (mostly impairment of investments in subsidiaries). Q4 FY25 swung to a standalone net loss of ₹42.2 crore versus a profit of ₹68.3 crore a year ago, also due to the exceptional item. The Board recommended a final dividend of ₹1 per share (10% of face value) subject to shareholder approval. B S R & Co. LLP issued an unmodified audit opinion, but flagged Emphasis of Matter on the ongoing SFIO investigation and the Supreme Court-mandated forensic audit of legacy RHT Health Trust transactions. The Board also appointed a new Secretarial Auditor (5-year term) and a Cost Auditor for FY26.
Operating business momentum is strong with healthy revenue and EBITDA growth, but bottom-line was distorted by non-cash subsidiary impairment; shareholders get a modest ₹1 dividend and clarity that legacy legal overhangs (SFIO, RHT matter) remain open though not impacting financials. The stock may take comfort from the clean audit opinion and margin expansion, while the NCD-driven rise in standalone debt (debt-equity from 0.07 to 0.22) is a watchpoint.